Sector News

Allergan buys regenerative medicine unit LifeCell for $2.9 billion

December 22, 2016
Life sciences

Drugmaker Allergan said on Tuesday it would buy LifeCell, a regenerative medicine unit owned by privately held Acelity LP, for $2.9 billion in cash, bringing the number of deals it has made this year to an even dozen.

LifeCell makes regenerative tissue products that are commonly used in breast reconstruction procedures and complex hernia surgeries to provide soft tissue support. The products will support Allergan’s portfolio of medical aesthetics, breast implants and tissue expanders, the company said.

Allergan chief executive Brent Saunders has described the company’s acquisition strategy as being one of “stepping stones.” Allergan’s deal to sell itself last year to Pfizer for $160 billion was dropped due to a change in tax law.

Allergan, best known for its Botox product, said LifeCell’s 2016 sales are expected to be $450 million and grow at a mid-single digit rate. It expects the deal to close in the first half of 2017.

Dublin-based Allergan, which was created through the combination of Actavis and Allergan, earlier this year sold its generics business to Teva Pharmaceutical Industries, freeing up cash for deals.Allergan has agreed to 12 deals this year, including the $1.7 billion acquisition of Tobira Therapeutics, maker of an experimental treatment for fatty liver disease, and $639 million acquiring Vitae, maker of an experimental drug to treat psoriasis.

Source: Reuters via Fortune

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.